(Dec. 8, 2023) – Nirsevimab (brand name Beyfortus) was approved by the United States Food and Drug Administration this summer for the prevention of Respiratory Syncytial Virus lower respiratory tract disease in neonates and infants born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. There are ongoing supply challenges with nirsevimab, which the manufacturer attributes to demand exceeding supply. In its
Oct. 23 Health Alert Network Advisory, the Centers for Disease Control and Prevention included recommendations for prioritizing available nirsevimab to infants at highest risk. The CDC further recommended providers suspend using nirsevimab in
palivizumab-eligible children from ages eight months to19 months for the 2023-2024 RSV season, advising these children should receive palivizumab per
American Academy of Pediatrics recommendations. The AAP offers many
nirsevimab administration resources, including a
Nirsevimab Administration Visual Guide.
--
Karen Braman